Affordable Access

Access to the full text

Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists

Authors
  • Morris, G.1
  • Walker, A. J.1
  • Berk, M.2, 3, 4, 5
  • Maes, M.1, 6
  • Puri, B. K.7
  • 1 Deakin University, School of Medicine, Geelong, 3220, Australia , Geelong (Australia)
  • 2 Deakin University, The Centre for Molecular and Medical Research, School of Medicine, Geelong, 3220, Australia , Geelong (Australia)
  • 3 Federal University of Ceará, Department of Clinical Medicine and Translational Psychiatry Research Group, Faculty of Medicine, Fortaleza, CE, 60430-040, Brazil , Fortaleza (Brazil)
  • 4 Deakin University, IMPACT Strategic Research Centre, School of Medicine, Geelong, 3220, Australia , Geelong (Australia)
  • 5 University of Melbourne, Orygen Youth Health Research Centre and the Centre of Youth Mental Health, The Florey Institute for Neuroscience and Mental Health and the Department of Psychiatry, Parkville, 3052, Australia , Parkville (Australia)
  • 6 Chulalongkorn University, Department of Psychiatry, Bangkok, Thailand , Bangkok (Thailand)
  • 7 Imperial College London, Department of Medicine, Hammersmith Hospital, London, W12 0HS, UK , London (United Kingdom)
Type
Published Article
Journal
Molecular Neurobiology
Publisher
Springer US
Publication Date
Oct 19, 2017
Volume
55
Issue
7
Pages
5767–5786
Identifiers
DOI: 10.1007/s12035-017-0793-y
Source
Springer Nature
Keywords
License
Green

Abstract

In the first part, the following mechanisms involved in different forms of cell death are considered, with a view to identifying potential therapeutic targets: tumour necrosis factor receptors (TNFRs) and their engagement by tumour necrosis factor-alpha (TNF-α); poly [ADP-ribose] polymerase (PARP)-1 cleavage; the apoptosis signalling kinase (ASK)-c-Jun N-terminal kinase (JNK) axis; lysosomal permeability; activation of programmed necrotic cell death; oxidative stress, caspase-3 inhibition and parthanatos; activation of inflammasomes by reactive oxygen species and the development of pyroptosis; oxidative stress, calcium dyshomeostasis and iron in the development of lysosomal-mediated necrosis and lysosomal membrane permeability; and oxidative stress, lipid peroxidation, iron dyshomeostasis and ferroptosis. In the second part, there is a consideration of the role of lethal and sub-lethal activation of these pathways in the pathogenesis and pathophysiology of neurodegenerative and neuroprogressive disorders, with particular reference to the TNF-α-TNFR signalling axis; dysregulation of ASK-1-JNK signalling; prolonged or chronic PARP-1 activation; the role of pyroptosis and chronic inflammasome activation; and the roles of lysosomal permeabilisation, necroptosis and ferroptosis. Finally, it is suggested that, in addition to targeting oxidative stress and inflammatory processes generally, neuropsychiatric disorders may respond to therapeutic targeting of TNF-α, PARP-1, the Nod-like receptor NLRP3 inflammasome and the necrosomal molecular switch receptor-interacting protein kinase-3, since their widespread activation can drive and/or exacerbate peripheral inflammation and neuroinflammation even in the absence of cell death. To this end, the use is proposed of a combination of the tetracycline derivative minocycline and N-acetylcysteine as adjunctive treatment for a range of neuropsychiatric disorders.

Report this publication

Statistics

Seen <100 times